Stockreport

GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision [Seeking Alpha]

GH Research PLC - Ordinary Shares  (GHRS) 
PDF GH001 demonstrated robust Phase 2b efficacy—a 15.5-point MADRS reduction at Day 8 and 73% six-month remission—with infrequent dosing and strong safety. GHRS maintains [Read more]